Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04054921 | Safety Study for Beta Thalassemia Subjects on PTG-300 | PHASE2 | COMPLETED | 34 | — | — | May 10, 2019 | Jul 31, 2020 | Jul 16, 2021 | 16 | United States, Greece +6 |
| NCT03802201 | Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia | PHASE2 | COMPLETED | 63 | — | — | Dec 19, 2018 | Jul 31, 2020 | Jul 16, 2021 | 33 | United States, Greece +7 |
the long-term safety and tolerability of PTG-300 in Beta Thalassemia.
NTD subjects who achieve an increase in Hgb without transfusion
TD subjects who achieve a reduction in red blood cell (RBC) units required over an 8 week period
| Arm | Type | Description |
|---|---|---|
| Interventions | EXPERIMENTAL | PTG-300 |
| PTG-300 Active | EXPERIMENTAL | Drug: PTG-300 Subcutaneous |
| Name | Type | Description |
|---|---|---|
| PTG-300 | DRUG | PTG-300 is a hepcidin Mimetic |
Inclusion Criteria: * NTD and TD β-thalassemia subjects who completed Week 12 and Week 16 respectively in Study PTG-300-02. Exclusion Criteria: * Subjects who discontinued prematurely from study 300-02 (before Week 12 in NTD and Week 16 in TD).
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. | AGIO | 5 | PHASE3 | Mitapivat, AG-348 |
| Bristol-Myers Squibb Company | BMY | 6 | PHASE3 | Luspatercept, ACE-536 |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | CTX001 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Etavopivat A, Etavopivat B, Etavopivat C |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN7999 |
| ICON Plc | ICLR | 1 | PHASE2 | SP-420 |
| Editas Medicine, Inc. | EDIT | 2 | PHASE1 | EDIT-301 |
| Illumina, Inc. | ILMN | 1 | — | Undisclosed |